SEC Filing · S-8
TransCode Therapeutics, Inc.
RNAZNASDAQEQUITYCurrent
SEC Filing
Company context
TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers We possess a diversified pipeline of therapeutic candidates, including two clinical stage assets, TTX-MC138, an antisense inhibitor of an oncogenic microRNA and Seviprotimut-L, a cancer vaccine. We also possess an oncolytic immunotherapy platform and three TTX-based pre-clinical stage assets.
Current securities
As-filed source
As filedOpen full document ↗